BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Announces Plans to Develop Micro Brain E-Tattoo Device for Growing Brain Diagnostics Market

January 21, 2021 11:40:08

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has begun development of a brain E-Tattoo device. The company announced that the innovative product will feature a temporary implanted or imprinted minimally invasive, subcutaneous graphene electrode paired with a micro EEG. The electrodes will connect to the micro EEG, which will be located behind the ear and which processes signals from the sensors and transfers the data to a cloud application. The proprietary offering is designed to provide continuous monitoring for data collection in patients with epilepsy and Alzheimer’s as well as patients who have suffered a stroke or who are dealing with other brain issues. Brain Scientific has filed a patent application for the Brain E-Tattoo device, and the company’s current focus is on safety testing, general proof of concept testing and performance testing. The small device is designed to have minimal impact on the wearer’s  daily life. “Our current EEG device is about the size of a stamp,” said Brain Scientific chairman Boris Goldstein in the press release. “By shrinking the technology, the system allows for continuous measurement during a person’s normal activities, while providing a non-intrusive way to monitor various disorders. We believe the future of EEG testing will be centered around the ability to gather more precise data through non-invasive measures of the brain via 3D temporary imprint or implanted graphene electrodes. By utilizing graphene, which has been called a “wonder material of the 21st century,” Brain Scientific believes the size of the electrodes can be thinner than a human hair and will allow brain activity monitoring with minimal distraction from everyday life.”

To view the full press release, visit

About Brain Scientific

Brain Scientific is a commercial-stage, health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. For more information about this company, please visit

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork